Affinity Asset Advisors, LLC
- SEC CIK
- 0001773195
- Latest filing
- Aug 13, 2026
Holdings in Q2 2024
Holdings as of Jun 30, 2024, filed Aug 14, 2024. Long positions only; changes compare share counts with Q1 2024.
- Positions
- 86
- +9 vs. Q1 2024
- Portfolio value
- $634.9M
- +$19.8M (+3.2%) vs. Q1 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| IOVAIovance Biotherapeutics, Inc. | COM | 100 | $802 | <0.1% | +100 | New | History |
| Rocket Pharmaceuticals, Inc.77313F114 | *W EXP 09/02/202 | 75,000 | $4.52K | <0.1% | 00.0% | Unchanged | – |
| GNLXGENELUX Corp | COM | 100,000 | $195.0K | <0.1% | +100,000 | New | History |
| PASGPassage BIO, Inc. | COM | 264,266 | $209.9K | <0.1% | 00.0% | Unchanged | History |
| RAPTRAPT Therapeutics, Inc. | COM | 75,000 | $228.8K | <0.1% | +75,000 | New | History |
| ORKAOruka Therapeutics, Inc. | COM | 72,484 | $277.6K | <0.1% | +72,484 | New | History |
| JBIOJade Biosciences, Inc. | COM | 200,000 | $332.0K | 0.1% | +200,000 | New | History |
| PMNProMIS Neurosciences Inc. | COM | 265,958 | $398.9K | 0.1% | 00.0% | Unchanged | History |
| MTVAMetaVia Inc. | COM | 89,222 | $431.8K | 0.1% | +89,222 | New | History |
| Immatics N.V.N44445117 | *W EXP 07/01/202 | 187,204 | $484.9K | 0.1% | 00.0% | Unchanged | – |
| QTTBQ32 Bio Inc. | COM | 27,777 | $498.6K | 0.1% | 00.0% | Unchanged | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 45,000 | $561.1K | 0.1% | +35,000+350.0% | Added | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 223,335 | $781.7K | 0.1% | −226,674−50.4% | Reduced | History |
| PBYIPuma Biotechnology, Inc. | COM | 250,000 | $815.0K | 0.1% | +250,000 | New | History |
| TECXTectonic Therapeutic, Inc. | COM | 58,331 | $960.7K | 0.2% | 00.0% | UnchangedConverted for a 1-for-12 split | History |
| KZRKezar Life Sciences, Inc. | COM | 1,761,778 | $1.06M | 0.2% | 00.0% | Unchanged | History |
| NKTXNkarta, Inc. | COM | 200,000 | $1.18M | 0.2% | +200,000 | New | History |
| TNGXTango Therapeutics, Inc. | COM | 150,274 | $1.29M | 0.2% | 00.0% | Unchanged | History |
| ARWRArrowhead Pharmaceuticals, Inc. | COM | 50,000 | $1.30M | 0.2% | −70,000−58.3% | Reduced | History |
| KYTXKyverna Therapeutics, Inc. | COM | 200,000 | $1.50M | 0.2% | +200,000 | New | History |
| ADCTADC Therapeutics SA | SHS | 474,744 | $1.50M | 0.2% | +474,744 | New | History |
| ARYDARYA Sciences Acquisition Corp IV | CL A | 133,500 | $1.53M | 0.2% | 00.0% | Unchanged | History |
| MRSNMersana Therapeutics, Inc. | COM | 767,000 | $1.54M | 0.2% | −233,000−23.3% | Reduced | History |
| ZYMEZymeworks Inc. | COM | 191,127 | $1.63M | 0.3% | +191,127 | New | History |
| VIRVir Biotechnology, Inc. | COM | 200,000 | $1.78M | 0.3% | +200,000 | New | History |
| WVEWave Life Sciences, Inc. | SHS | 375,000 | $1.87M | 0.3% | +88,415+30.9% | Added | History |
| NAMSWNewAmsterdam Pharma Co N.V. | *W EXP 11/22/202 | 202,599 | $1.92M | 0.3% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 150,000 | $1.95M | 0.3% | +150,000 | New | History |
| BBIOBridgeBio Pharma, Inc. | COM | 100,000 | $2.53M | 0.4% | +50,000+100.0% | Added | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 250,000 | $2.56M | 0.4% | 00.0% | Unchanged | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 69,999 | $2.64M | 0.4% | −30,001−30.0% | Reduced | History |
| NXTCNextCure, Inc. | COM | 1,687,955 | $2.68M | 0.4% | +328,918+24.2% | Added | History |
| OLMAOlema Pharmaceuticals, Inc. | COM | 275,000 | $2.98M | 0.5% | +275,000 | New | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 500,512 | $3.02M | 0.5% | −527,356−51.3% | Reduced | History |
| BDTXBlack Diamond Therapeutics, Inc. | COM | 650,000 | $3.03M | 0.5% | +650,000 | New | History |
| CNTXContext Therapeutics Inc. | COM | 1,619,140 | $3.25M | 0.5% | +1,290,323+392.4% | Added | History |
| State Street SPDR S&P Biotech ETF78464A870 | ETF | 37,550 | $3.48M | 0.5% | +37,550 | New | – |
| IMTXImmatics N.V. | SHS | 300,000 | $3.49M | 0.5% | −50,000−14.3% | Reduced | History |
| FRNMFreenome, Inc. | CL A ORD SHS | 350,000 | $3.52M | 0.6% | +350,000 | New | History |
| DYNDyne Therapeutics, Inc. | COM | 100,000 | $3.53M | 0.6% | +100,000 | New | History |
| ROIVRoivant Sciences Ltd. | SHS | 351,587 | $3.72M | 0.6% | −148,413−29.7% | Reduced | History |
| MLYSMineralys Therapeutics, Inc. | COM | 327,959 | $3.84M | 0.6% | 00.0% | Unchanged | History |
| HLVXHilleVax, Inc. | COM | 265,859 | $3.84M | 0.6% | +265,859 | New | History |
| ELEVElevation Acquisition Group Inc. | COM | 1,468,825 | $3.97M | 0.6% | +200,000+15.8% | Added | History |
| PCVXVaxcyte, Inc. | COM | 60,000 | $4.53M | 0.7% | −20,000−25.0% | Reduced | History |
| CGEMCullinan Therapeutics, Inc. | COM | 263,817 | $4.60M | 0.7% | +5,229+2.0% | Added | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 155,000 | $5.30M | 0.8% | −5,000−3.1% | Reduced | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 550,000 | $5.48M | 0.9% | +550,000 | New | History |
| ERASErasca, Inc. | COM | 2,499,431 | $5.90M | 0.9% | +2,499,431 | New | History |
| SVRASavara Inc | COM | 1,546,850 | $6.23M | 1.0% | +396,850+34.5% | Added | History |
| Karyopharm Therapeutics Inc.48576UAA4 | NOTE 3.000%10/1 | – | $6.30M | 1.0% | – | New | – |
| GERNGeron Corp | COM | 1,500,000 | $6.36M | 1.0% | −1,000,000−40.0% | Reduced | History |
| AXSMAxsome Therapeutics, Inc. | COM | 80,000 | $6.44M | 1.0% | −59,758−42.8% | Reduced | History |
| MRUSMerus N.V. | COM | 125,000 | $7.40M | 1.2% | +125,000 | New | History |
| RZLTRezolute, Inc. | COM NEW | 1,850,000 | $7.96M | 1.3% | +250,000+15.6% | Added | History |
| Omeros Corp682143AG7 | NOTE 5.250% 2/1 | – | $8.08M | 1.3% | – | – | – |
| NAMSNewAmsterdam Pharma Co N.V. | ORDINARY SHARES | 423,155 | $8.13M | 1.3% | +136,955+47.9% | Added | History |
| INSMINSMED Inc | COM PAR $.01 | 125,000 | $8.38M | 1.3% | +125,000 | New | History |
| MORFMorphic Holding, Inc. | COM | 250,573 | $8.54M | 1.3% | +25,573+11.4% | Added | History |
| Coherus Biosciences Inc19249HAB9 | NOTE 1.500% 4/1 | – | $8.64M | 1.4% | – | – | – |
| ATXSAstria Therapeutics, Inc. | COM | 975,606 | $8.88M | 1.4% | +130,000+15.4% | Added | History |
| IMVTImmunovant, Inc. | COM | 346,088 | $9.14M | 1.4% | +61,088+21.4% | Added | History |
| NARIInari Medical, Inc. | Stock | 200,000 | $9.63M | 1.5% | +25,000+14.3% | Added | History |
| VRNAVerona Pharma plc | SPONSORED ADS | 700,000 | $10.1M | 1.6% | −117,833−14.4% | Reduced | History |
| ESTAEstablishment Labs Holdings Inc. | COM | 223,407 | $10.2M | 1.6% | +58,818+35.7% | Added | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 1,135,702 | $10.3M | 1.6% | +305,156+36.7% | Added | History |
| CLYMClimb Bio, Inc. | COM | 1,670,661 | $11.9M | 1.9% | +1,670,661 | New | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 513,420 | $12.1M | 1.9% | +103,420+25.2% | Added | History |
| INZYInozyme Pharma, Inc. | COM | 2,856,252 | $12.7M | 2.0% | +213,733+8.1% | Added | History |
| KURAKura Oncology, Inc. | COM | 650,000 | $13.4M | 2.1% | −80,492−11.0% | Reduced | History |
| VERAVera Therapeutics, Inc. | CL A | 375,000 | $13.6M | 2.1% | −95,000−20.2% | Reduced | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 4,300,000 | $15.0M | 2.4% | +925,000+27.4% | Added | History |
| NUVLNuvalent, Inc. | COM | 200,000 | $15.2M | 2.4% | +50,000+33.3% | Added | History |
| ALKSAlkermes plc. | SHS | 650,000 | $15.7M | 2.5% | +575,000+766.7% | Added | History |
| ONCBeOne Medicines Ltd. | ADR | 110,000 | $15.7M | 2.5% | +27,857+33.9% | Added | History |
| Alnylam Pharmaceuticals, Inc.02043QAB3 | NOTE 1.000% 9/1 | – | $16.2M | 2.6% | – | – | – |
| BridgeBio Pharma, Inc.10806XAB8 | NOTE 2.500% 3/1 | – | $17.3M | 2.7% | – | – | – |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 475,400 | $17.6M | 2.8% | −34,600−6.8% | Reduced | History |
| NRIXNurix Therapeutics, Inc. | COM | 912,000 | $19.0M | 3.0% | +101,747+12.6% | Added | History |
| CERECerevel Therapeutics Holdings, Inc. | COM | 500,000 | $20.4M | 3.2% | +200,000+66.7% | Added | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 515,000 | $23.1M | 3.6% | +45,000+9.6% | Added | History |
| TEVATeva Pharmaceutical Industries Ltd | SPONSORED ADS | 1,450,000 | $23.6M | 3.7% | +50,000+3.6% | Added | History |
| ACLXArcellx, Inc. | COMMON STOCK | 460,000 | $25.4M | 4.0% | +160,000+53.3% | Added | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 110,000 | $30.8M | 4.9% | −5,000−4.3% | Reduced | History |
| APGEApogee Therapeutics, Inc. | COM | 836,283 | $32.9M | 5.2% | +244,190+41.2% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 994,227 | $38.8M | 6.1% | +156,840+18.7% | Added | History |
Options (12)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| SPYSPDR S&P 500 ETF Trust | ETF | $190.5M | – |
| TEVATeva Pharmaceutical Industries Ltd | SPONSORED ADS | – | $18.7M |
| CERECerevel Therapeutics Holdings, Inc. | COM | – | $10.2M |
| SANASana Biotechnology, Inc. | COM | $2.84M | – |
| TWSTTwist Bioscience Corp | COM | – | $2.22M |
| RAPTRAPT Therapeutics, Inc. | COM | $1.66M | – |
| FULCFulcrum Therapeutics, Inc. | COM | – | $1.55M |
| IMVTImmunovant, Inc. | COM | – | $1.43M |
| IOVAIovance Biotherapeutics, Inc. | COM | $1.20M | – |
| PCVXVaxcyte, Inc. | COM | – | $1.13M |
| ALXOAlx Oncology Holdings Inc | COM | – | $603.0K |
| INSMINSMED Inc | COM PAR $.01 | $582.9K | – |
Sold out since Q1 2024 (16)
Positions held at the end of Q1 2024 that are gone from this filing.
| Security | Class | Shares in Q1 2024 | Value in Q1 2024 | % of portfolio in Q1 2024 | History |
|---|---|---|---|---|---|
| APLSApellis Pharmaceuticals, Inc. | COM | 165,000 | $9.70M | 1.6% | History |
| CATXPerspective Therapeutics, Inc. | COM | 5,100,000 | $6.07M | 1.0% | History |
| ABSIAbsci Corp | COM | 1,025,000 | $5.82M | 0.9% | History |
| CYTKCytokinetics Inc | COM NEW | 80,000 | $5.61M | 0.9% | History |
| FULCFulcrum Therapeutics, Inc. | COM | 550,339 | $5.20M | 0.8% | History |
| KRYSKrystal Biotech, Inc. | COM | 26,746 | $4.76M | 0.8% | History |
| VKTXViking Therapeutics, Inc. | COM | 50,000 | $4.10M | 0.7% | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 75,000 | $3.77M | 0.6% | History |
| ITCIIntra-Cellular Therapies, Inc. | COM | 50,000 | $3.46M | 0.6% | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 450,000 | $2.95M | 0.5% | History |
| PTGXProtagonist Therapeutics, Inc | COM | 100,000 | $2.89M | 0.5% | History |
| RGNXREGENXBIO Inc. | COM | 110,000 | $2.32M | 0.4% | History |
| BSXBoston Scientific Corp | Stock | 25,000 | $1.71M | 0.3% | History |
| TRMLTourmaline Bio, Inc. | COM | 50,000 | $1.15M | 0.2% | History |
| TVTXTravere Therapeutics, Inc. | COM | 125,000 | $963.8K | 0.2% | History |
| Cassava Sciences Inc14817C115 | *W EXP 11/15/202 | 24,200 | $97.5K | <0.1% | – |